Join to View Full Profile
2010 Olathe BlvdKansas City, KS 66103
Phone+1 913-588-3974
Dr. Ripp is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jacob Ripp, DO, is an internal medicine specialist based in Kansas City, KS. He completed his residency in internal medicine at the University of Kansas School of Medicine from 2019 to 2022, after graduating from A. T. Still University Kirksville College of Osteopathic Medicine in 2019. Dr. Ripp has an active publication record, with recent research focused on advanced gastroesophageal cancer, the interplay of immunosuppression and immunotherapy in cancer and COVID-19 patients, and the use of oncolytic viruses with immune checkpoint inhibitors. His work has been published in notable journals such as Cell Reports Medicine, JAMA Oncology, Frontiers in Bioscience, Journal of Geriatric Oncology, and Clinical Colorectal Cancer.
Education & Training
- University of Kansas School of MedicineResidency, Internal Medicine, 2019 - 2022
- A. T. Still University Kirksville College of Osteopathic MedicineClass of 2019
Certifications & Licensure
- SC State License 2025 - 2027
- NC State License 2022 - 2025
- KS State License 2019 - 2022
- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 22 citationsCabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.Anwaar Saeed, Robin Park, Junqiang Dai, Raed Al-Rajabi, Anup Kasi
Cell Reports. Medicine. 2023-02-21 - 30 citationsInterplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.Ziad Bakouny, Chris Labaki, Punita Grover, Joy Awosika, Shuchi Gulati
JAMA Oncology. 2023-01-01 - 11 citationsOncolytic Viruses as an Adjunct to Immune Checkpoint Inhibition.Jacob Ripp, Stijn Hentzen, Anwaar Saeed
Frontiers in Bioscience. 2022-05-10
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: